COVID-19 vaccine trial: vital signs of Pune volunteers normal, says doctor

They have no pain, fever, side reaction or any systemic illness, says official

August 27, 2020 11:14 pm | Updated 11:55 pm IST - Pune

One test at a time: COVID-19 samples being collected at a mobile unit in New Delhi on Thursday.

One test at a time: COVID-19 samples being collected at a mobile unit in New Delhi on Thursday.

Vital health parameters of the two volunteers who have been administered the Oxford COVID-19 vaccine candidate at a medical college here as part of the phase 2 clinical trial, are normal, a senior official from the medical facility said on Thursday.

Two men, aged 32 and 48, were given the first shot of the ‘Covishield’ vaccine, being manufactured by the Pune-based Serum Institute of India (SII), at Bharati Vidyapeeth’s Medical College and Hospital on Wednesday. The dose will be repeated after one month, an official said.

‘In touch with duo’

“Since yesterday, our medical team is in touch with the two volunteers and both are fine. They do not have any pain, fever, injection side reaction or systemic illness post-vaccination,” Jitendra Oswal, the medical college and hospital’s deputy medical director, said.

After the vaccine was administered on Wednesday, both the volunteers were observed for 30 minutes and later allowed to go home, he said.

“They have been given all the necessary emergency numbers [to contact in case of need] and our medical team is also conducting follow-ups with them,” he added.

The vaccine dose would be repeated on both the volunteers after one month, the hospital’s medical director, Sanjay Lalwani, said on Wednesday.

More candidates

He said 25 candidates would be given the vaccine in the next seven days. Sonali Palkar, in charge of the medical college’s research cell, said four or five persons were screened on Wednesday and a decision to administer the vaccine to them as part of the clinical trial was subject to their COVID-19 and antibody test reports.

The SII, the world’s largest vaccine maker, has signed an agreement to manufacture the potential vaccine developed by the Jenner Institute of Oxford University, in collaboration with British-Swedish pharma company AstraZeneca.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.